Internet Drug News.com
Pharmaceutical News & Information; Updated Daily Since 1998

Research/Regulatory
Drug Coupons Database
Medical Dictionary
Clinical Trials In Progress
Clinical Trial Results
SEARCH Medline
Medline Plus  by Topic
Amedeo
Viagra
CDER LIst - (FDA)
Gen Info;Site Dissection

Boiler Plate Patient Info
Advisory Documents
Database Of Ongoing Clinical Trials
New Drug Approvals.org
Dear Doctor Letter Database
Drugs@FDA [gateway]
Drug Approvals Report

Newly filed ANDA's
Product Data Database
Orange Book
Recently Approved Drugs (CenterWatch)
Upcoming Meetings

Medwatch Safety
Recalls/Alerts
NDC Code Directory

Postmarketing Safety Data

Warning Letters
Medwatch Top Pages
Site Map
Pharmaceutical Sales
Diabetes Drugs
Drug Information Databases
Pharmaceutical Sales

Search By Definition

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here
.

***********
Worth A Click
MedicalNewsToday.com
PharmaGossip
Pharmalot
Viagra For Women; Investigative Report
The Eyes Have It
Biotech & Pharma Patent Law & News Blog
FDA Law Blog
BioMedReports.com
PharmTechTalk
Canada Pharmacy News
NewHopeBlog.com
PharmaJobsBlog
Drug Wonks
The Healthcare Blog Visual Being
Drug Injury Watch
AdChat
AdPharm
WorldPharmanews
Before You Take That Pill
Pharma Poland
The Science Business
BNET Pharma Beat
World Of DTC Marketing.com

Pharmaceutical News Harvest ™

11/26 Fast Takes
Bayer Said to Explore Sale of $2.5 Billion Glucometer Business
Bloomberg


11/26
Express Locks Our 66 Meds For 2015 Up From 48 In 2014
CVS To Ban 95 in '15 Up From 70 In '14
- Advair back, Epogen, Aranesp out
More Medicine Goes Off Limits in Drug-Price Showdown … goal is to use its clout to shift market share to drug companies willing to give it better discounts … Drug companies that "think they can charge whatever they want" in competitive categories "run the risk of being excluded …[Bloomberg]
See Also: Express 2015 Formulary | Express 2015 excluded drugs
Editor's Note: Newly excluded drugs include: Aranesp, Duexis, Zohydro
See Also: CVS 2015 Formulary | CVS 2015 excluded drugs
Editor's Note: Noteworthy excluded drugs include: Byetta, Humalog, Farxiga, Apidra, Symbicort

11/26
Seven Years Later, Prime Suspect In Drug Rep Murder Yet To Face Trial
Remembering Nailah Franklin … Reginald Potts Jr., 32, was charged with murder and remains in jail awaiting trial … Seven years after he was charged in the slaying of a Nailah Franklin, Reginald Potts has yet to go to trial. And as of late October 2014, he changed his legal team again, making a January trial date unlikely … [Chicago Tribune]

11/26 Legislation To Legalize Canadian Reimportation Revived
Lawmakers Look for Ways to Provide Relief for Rising Cost of Generic Drugs … ohn McCain will revive stalled legislation to allow some prescription imports from Canada. And Maine is testing out a hotly contested new law that allows its residents to buy drugs from overseas, flouting United States policy …[NY Times]
Editor's Note: He's such a maverick, that John McCain is.

11/26
Statins: JAMA Says 100% Of Men Should Take Them Even If Healthy
Elderly should take cholesterol-lowering statins: US study … 97 percent of people in the age group, and 100 percent of men, should be on the medication even if their cholesterol levels are normal … [AFP]

11/26
AbbVie To Gilead: Get Ready For European  Rumble
- AbbVie answer to Harvoni: price will be similar
AbbVie Takes Aim at Gilead Sciences … approval of AbbVie's Exviera and Viekirax (the two drugs used in the three pill cocktail) for use in hepatitis C patients should result in an official approval from the EMA unlikely that AbbVie will price its cocktail significantly less than the $94,500 that Gilead Sciences is charging for Harvoni.   …[Motley Fool]

11/24
Fast Takes
Triclosan: Antibacterial Soap Ingredient Linked To Liver Damage, Cancer in Mice
LA Times
How nucleoside reverse transcriptase inhibitors may be able to treat blindness
Forbes
FDA awards breakthrough status to Sanofi-Regeneron's dermatitis drug
Healio

11/24
Senate Panel Inquisition Regarding Generic Price Spikes
- Pharmacists forced to absorb price increases, lose money
Soaring generic drug prices draw Senate scrutiny …  doxycycline hyclate, rose more than 8,280 percent during a six-month period from an average of $20 per bottle to $1,849 per bottle … albuterol sulfate, a common asthma treatment, shot from an average of $11 per bottle in October 2013 to $434 per bottle in April, an increase of over 4,000 percent …[AP]
Editor's Note: Prices go up, that's a fact of life.  The bigger issue is that large PBMs who own mail order pharmacies take too long to update reimbursement prices,  forcing pharmacists to lose money on scripts or turn patients away.

11/24
Sanofi: No Plans To Jettison Inhaled Insulin; Hopes For Expanded Indications
MannKind's Afrezza Remains in Sanofi's Plans, RBC Says …  two or more oral agents and resisting moving on to injectable insulin and those who need meal-time … negotiations with the FDA over post-approval studies that could expand Afrezza …[Barrons]

11/24
Takeda: US Pharma Prez Is History: Quit? Fired?
Takeda Pharmaceuticals president quits … point in his career where he decided to explore his options … hired on at Takeda in 1992 as a sales rep and worked his way up … couldn't be reached for comment …[Crains]
Editor's Note: It's no secret that the recent Contrave launch was hobbled by bottlenecks associated with a direct delivery program.  The website was overloaded and potentially, some sales were lost.   

11/24
Sanofi Banks On Success Of Lantus Successor
Sanofi offers glimpse of next-gen. insulin strategy …   52% of US endocrinologists are aware of the drug …  77% say they're willing to prescribe Toujeo …  hopes to expand its patient base by a million new patients per year …[MM&M]
Editor's Note: Adds information regarding Afrezza launch strategy.

Fast Takes
Vancouver Experiments With Prescription Heroin
The Atlantic
Aurobindo Recalls Gabapentin 300 mg caps
CNBC
Why These Big Pharma Stocks (Bristol, Pfizer, Lilly) Could Plunge Next Year
Motley Fool
Amgen pulls plug on stomach cancer drug
AP
Express Scripts is Sued by Compound Pharmacies for Denying Claims
Pharmalot


11/25
AZN CEO Boast: We're On Track To Sell $45Bln 
Worth Of Drugs
- Grandstanding statement to ward off Pfizer takeover hopes
AstraZeneca says a U.S. expansion is needed to realize pipeline potential … repeating the pipeline potential mantra in hopes of convincing Pfizer not to return with its hostile intentions. The CEO and his board repeatedly beat back Pfizer offers that eventually reached $117 billion …[Fierce Pharma]

11/25
Lundbeck CEO Ousted In Stock Scandal
- Resignation comes as new product launches near
Lundbeck CEO Resigns Over a 'Serious' Breach of Conduct … sends a powerful message. Many companies would be happy to give a slap on the wrist … failing to tell the board that he received 55 shares from the founder of Stratified Medical, a privately held biotech in which the drug maker later made an investment …[Pharmalot]
Lundbeck's CEO resigns after breach of company rules …  timing is really bad for Lundbeck facing expiring patents for key products, and with launches and upcoming approvals for new products in the next couple of years …[Reuters]

11/25
American Merck Buys Rights To Promising Ebola Vaccine
Drug Giant Merck & Co. (MRK) Buys Rights To NewLink Genetics Ebola Vaccine … utilizes an attenuated strain of a vesicular stomatitis virus. A piece of the Ebola virus genetic code is inserted into the vesicular stomatitis virus, causing it to produce an Ebola virus protein  …[Biospace]

11/25
NEJM Noodnicks Urge Crackdown On Pharma Digital Marketing
Researchers Seek New Regulations for Digital Pharma Marketing … doctors reporting receiving visits from sales reps has fallen to 55% … policies intended to limit the nature of marketing are lagging behind "but the medical profession can enact policies to ensure that patients, not advertising, remain the focus of care …[DDD]

11/25
AstraZeneca Loses Bid to End 'Pay-For-Delay' Nexium Trial
AstraZeneca Loses Bid to End 'Pay-For-Delay' Nexium Trial … trial over AstraZeneca's "pay-for-delay" deals to block early competition to Nexium is the first of its kind since the U.S. Supreme Court last year opened the door, finding companies can be sued over such deals …[Bloomberg]

11/25
Take Over A Drug Company, Get Rid Of Their People; The Actavis Method
-They did it to Forest, now it's Allergan's turn
Actavis Plans Job Cuts, China Expansion for Allergan … we're going to have do some cutting but we're going to do that very carefully because these are two growing companies …[Bloomberg]

11/25
Senator's Threaten Generic Drugmakers With Form Of Price Control
- Price raise tax penalty would be 1st of its kind
Should Generic Drug Makers pay Medicaid Rebates Tied to Inflation? … would require generic drug makers to pay additional rebates to state Medicaid programs for any medicine that increases in price faster than the inflation rate … [Pharmalot]

11/24
Fast Takes
Triclosan: Antibacterial Soap Ingredient Linked To Liver Damage, Cancer in Mice
LA Times
How nucleoside reverse transcriptase inhibitors may be able to treat blindness
Forbes
FDA awards breakthrough status to Sanofi-Regeneron's dermatitis drug
Healio


11/24
Senate Panel Inquisition Regarding Generic Price Spikes
- Pharmacists forced to absorb price increases, lose money
Soaring generic drug prices draw Senate scrutiny …  doxycycline hyclate, rose more than 8,280 percent during a six-month period from an average of $20 per bottle to $1,849 per bottle … albuterol sulfate, a common asthma treatment, shot from an average of $11 per bottle in October 2013 to $434 per bottle in April, an increase of over 4,000 percent …[AP]
Editor's Note: Prices go up, that's a fact of life.  The bigger issue is that large PBMs who own mail order pharmacies take too long to update reimbursement prices,  forcing pharmacists to lose money on scripts or turn patients away.

11/24
Sanofi: No Plans To Jettison Inhaled Insulin; Hopes For Expanded Indications
MannKind's Afrezza Remains in Sanofi's Plans, RBC Says …  two or more oral agents and resisting moving on to injectable insulin and those who need meal-time … negotiations with the FDA over post-approval studies that could expand Afrezza …[Barrons]

11/24
Takeda: US Pharma Prez Is History: Quit? Fired?
Takeda Pharmaceuticals president quits … point in his career where he decided to explore his options … hired on at Takeda in 1992 as a sales rep and worked his way up … couldn't be reached for comment …[Crains]
Editor's Note: It's no secret that the recent Contrave launch was hobbled by bottlenecks associated with a direct delivery program.  The website was overloaded and potentially, some sales were lost.   

11/24
Sanofi Banks On Success Of Lantus Successor
Sanofi offers glimpse of next-gen. insulin strategy …   52% of US endocrinologists are aware of the drug …  77% say they're willing to prescribe Toujeo …  hopes to expand its patient base by a million new patients per year …[MM&M]
Editor's Note: Adds information regarding Afrezza launch strategy.
11/21 U.S. Per Capita Drug Spending to Hit $1409 by 2018
World's Drug Bill Will Reach $1.3 Trillion in 2018 .... IMS forecasts Americans will pay an average of $1,409 a person in 2018, up from $1,075 last year, a faster rate of growth than the expansion of the population .... Bloomberg

11/21 Sanofi Parades 18 New Products in Pipeline for Next Five Years
Sanofi's Sluggish Diabetes Growth Nips at Ambitious Product Plan .... Next year, Sanofi starts losing patent exclusivity on its top-selling product, Lantus insulin, increasing the pressure to boost growth with new treatments such as Praluent for cholesterol and the world's first dengue vaccine .... Bloomberg

11/21 Purdue New Pain Pill: "Hysingla ER" Fights Abuse with Gel Formulation
Purdue Pharma Wins Approval for Abuse-Deterrent Pain Pill .... FDA has cleared the drug Hysingla ER with a label that indicates the tablet is difficult to abuse via injection or snorting .... Bloomberg

11/21 Former Merck Cancer Research Boss Gary Gilliland to Head Research Center
New 'Hutch' Director Aims To Push Toward Cancer Cures Based On The Immune System .... The exciting thing about drugs like Merck's PD-1 blocker, which is now approved for melanoma patients who have failed other drugs, is that they actually result in some patients having durable responses in tough diseases like melanoma and lung cancer. .... Forbes/Matthew Herper

11/21 Cost of Drug Brands Typically Used by Older People Up 13% in 2013
AARP: Brand name drug prices jump .... The increase is more than eight times the 1.5 percent inflation rate, and the highest annual increase since 2004, the group said. And the price of seven brand name drugs rose by more than 30 percent. .... Greenville Online

11/21 Running the Numbers on New Novartis HF Drug
How to prep for a 'megablockbuster' launch? Novartis lines up cost-savings data .... The experimental med cut ER visits by 30% and reduced hospitalizations by 16%, compared with an older standard treatment, elanapril. .... Fierce Pharma Marketing

11/21 Need to Save on Sovaldi But Don't Care for Cairo? Hop a Plane to Paris
France negotiates lowest price in Europe for Gilead Sciences Sovaldi .... The Economic Committee for Health Products fixed the price for a 28-tablet pack of Sovaldi at 13,667 euros ($17,138), which is 5000 euros ($6269) lower than the original price, while a 12-week course of treatment will cost 41,000 euros ($51,411), compared with 56,000 euros ($70,220) previously. .... First Word Pharma

11/21 Diabetes Costs Top $1,000 for Every American
Cost of Diabetes Care Keeps Climbing .... The total includes $244 billion in medical costs -- including doctor's office and hospital visits, prescription drugs, and other health conditions such as hypertension and kidney complications -- and $78 billion in lost work productivity .... HealthDay News

11/21 Three Month Version of "Invega Sustenna" Goes to FDA for Review
Janssen files four-times-a-year schizophrenia shot .... It is hoped that the new three-month version will go even further in boosting treatment adherence rates compared to the monthly version .... Pharma Times

11/21 Systematic Review of Adherence Literature Finds Few Solutions
Only half of patients take their medications as prescribed .... Many stop taking medication all together and others do not follow the instructions for taking it properly. This has been the case in many different diseases for at least the last half a century. .... Medical Xpress

11/21 Heavy Drinking Kills 88,000 People a Year, Even if They Are Not Alcoholic
Most heavy drinkers are not alcoholics, U.S. study finds .... Contrary to popular opinion, only 10 percent of U.S. adults who drink too much are alcoholics .... [Reuters]

11/21 Internet Drug News Fast Takes:
U.S. states get more, spend more on Medicaid under Obamacare
Reuters
Six physician personas every executive will recognize
Advisory Board
Woman finds herself trapped in CVS drug store
CNNWire
11-country survey of older adults: Americans sicker but have quicker access to specialists
Health Affairs

11/20 Single Infusion of Specially Tailored Virus Defeats $250,000/Year Hemophilia
Gene therapy found effective in hemophilia B .... Ten patients with severe hemophilia B have remained cured of the inherited bleeding disorder for as long as three years thanks to gene therapy .... [Reuters]

11/20 Critics Say Open Kimono Law Doesn't Go Far Enough
U.S. government proposes more transparency in clinical trials .... U.S. health officials on Wednesday proposed significantly expanding what researchers are required to report about clinical trials of drugs, devices, and other interventions .... [Reuters]

11/20 Otezla for Psoriatric Arthritis Matches Methotrexate + a Biologic
ACR: Otezla Benefit Durable in PsA .... Among patients receiving 20 mg of apremilast twice daily for 2 years, 20% improvements on the criteria of the American College of Rheumatology (ACR20) were seen in 64.8%, and among those given 30 mg twice daily, 57.3% had ACR20 responses .... [Medpage Today]

11/20 Accelerated Review Voucher Now Worth $125 Million; Buyer Won't Disclose for What Drug
Gilead Buys Shortcut For FDA Drug Review For $125 Million .... In an auction, Gilead Sciences, a maker of HIV and hepatitis medicines, just bought a coupon good for the accelerated review of a drug of the company's choice from Knight Therapeutics .... [Medpage Today]

11/20 Land of the Bean and Cod Draws Another Company
'More Biotechy?' Shire to Move US HQ and 500 Jobs to Greater Boston .... Shire, which is best known for selling ADHD pills such as Adderall XR, will move all of its R&D and commercial operations from Chesterbrook, Pa., to Lexington, Ma., which will become its new U.S. headquarters .... [Pharmalot]

11/20 FDA Still Has Nagging Fear That You Don't Pay Full Attention to Drug Ad Warnings
FDA Plans Huge Study on How Public Understands Drug Risk .... The proposed study will test more than 10,000 patients in a bid to examine how they assess drug risk independently of other products. FDA will test patients in eight groups (four chronic pain ads and four hypertension ads) split between a population of those with hypertension or chronic pain and those from a "general population." .... [Regulatory Focus]

11/20 If LDL = 50 is Good, is LDL = 40 Better?
Will The IMPROVE-IT Results Impact The Thinking of The FDA And Payers on LDL-Cholesterol Lowering Drugs? .... The FDA might require an IMPROVE-IT type outcome study for each PCSK-9 inhibitor before approving these drugs in order to demonstrate the long-term benefits and safety of such unprecedented LDL lowering .... [Forbes/John LaMatinna]

11/20 Payers Putting The Brakes on Hard on Harvoni
Payers' hep C delay tactics work: Coverage hurdles may be dampening Harvoni script growth .... While everyone gets access to the treatment eventually, he said, about 90% fail to get approval on the first attempt, and it typically takes two to four weeks for patients to actually start a regimen .... [Fierce Pharma]

11/20 NPs and PAs Get Rep Attention
Pharma deploys reps with helping hands to target stealth prescribers .... Mid-level healthcare professionals like nurse practitioners and physician assistants often play an integral role in physician prescribing. Their names just don't show up in prescription data that drugmakers use to target sales pitches .... [Fierce Pharma Marketing]

11/20 Medicaid Inflation Rebate May Tempt Drugmakers to Aim High in Pricing
Congressional Research Service wants to know: Is Medicaid rebate contributing to high drug prices? .... The rebate program could invite gamesmanship, encouraging higher launch prices that will effectively offset or recover the cost of Medicaid rebates by reducing the additional inflation rebate, especially for drugs such as Solvaldi that have a backlog of demand and no competition .... [BioWorld]

11/20 Internet Drug News Fast Takes:
Royalty Pharma buys royalties on Vertex Pharma drugs for $3.3 bln
Reuters
A Lack of Bacteria Can Make You Overweight
WSJ
AZ seeks leg up in antiplatelet market with Brilinta antidote
PMLiVE
This IoT Device Is Actually FDA Approved
Forbes
Heart Drug, Losartan, Falls Short of Promise in a Study
NY Times


11/19 How Much Does Developing a New Drug Really Cost?
Tufts: average drug costs $2.6 bln to develop; critics wary .... The center said its updated estimate of $2.56 billion is based on data from 10 drugmakers on 106 drugs tested from 1995 to 2007 .... [Reuters]

11/19 Painkiller Suit Details Promotion Tactics
Painkiller marketing secrets? Check Chicago's unredacted suit against Endo, Purdue, Cephalon, et al. .... Actavis trained reps and physician-speakers to say that opioid doses could be raised during long-term use, without ever hitting a dose ceiling--and that long-term use of opioids was safer than long-term therapy with drugs like acetaminophen or NSAIDS, which include aspirin and ibuprofen .... [Fierce Pharma Marketing]

11/19 Soriot Touts AZN's Oncology Line-Up
AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer .... AstraZeneca's showcase event came eight days before British takeover rules allow Pfizer to renew its pursuit, an option some investors now see as unlikely after the U.S. company signed a major cancer drug deal with Germany's Merck KGaA .... [Reuters]

11/19 Actavis CEO Has Done $99 Billion in Deals in His Career
Actavis Surges to Top Drugmaker Ranks With Acquisitions .... The plan is to cut $1.8 billion in annual costs and use its sales force, focused on primary-care doctors, to generate more revenue from Allergan drugs like Botox, which have been traditionally marketed to specialists. .... [Bloomberg]

11/19 Fight Over Thousand-Dollar Pain Creams
Drug Compounders Sue Express Scripts Over Rejected Claims .... Express Scripts is targeting or blocking 1,000 compounding ingredients, part of a plan it said would save clients 95 percent of their costs while affecting 0.6 percent of patients served .... [Bloomberg]

11/19 Dissatisfied Women Find Advocate
Is Pink Viagra a 'Sham Drug'? .... The LA Times op-ed reports that #WomenDeserve and eventhescore.org were developed by Sprout Pharmaceuticals, which has been seeking FDA approval for its female sexual dysfunction drug flibanserin. .... [Yahoo]

11/19 Insider Responds to Pharma-Bashing on Prices
The Real Cost of "High-Priced" Drugs .... Given the prices after patents expire, innovative drugs essentially become ongoing "gifts" to society .... [Harvard Business Review]

11/19 Zetia Works, But Alirocumab Works Even Better
PCSK9s stalk Merck's Vytorin .... A head-to-head trial with Zetia showed that the PCSK9 "produced significantly greater LDL-C reductions versus ezetimibe” after 24 weeks of treatment .... [MM&M]

11/19 Pradaxa Studies Released at AHA
Analyses support Pradaxa safety profile .... The DOD analysis showed that patients taking Pradaxa were less likely to have a stroke and major bleeding issues compared to those taking warfarin, but the Pradaxa group experienced more incidents of risk for lower gastrointestinal bleeding.... Brigham and Women's Hospital's study observed that Pradaxa patients also had fewer strokes, but exhibited fewer major bleeding events in all areas compared to warfarin patients .... [MM&M]

11/19 Generic-Blocking Petitions Dropping Off
FDA Cracking Down on Attempts to Delay Entry of Generic Drugs .... DA is now out with its sixth report since the passage of FDAAA, and agency records show that petitions meant to delay approval of other drugs—505(q) petitions—appear to be at an all-time low .... [Regulatory Focus]

11/19 Internet Drug News Fast Takes:
Men who 'monitor' their prostate cancers have high quality of life
Reuters
New blood test detects Alzheimer's—10 years before you get it
Reuters
Deaths From Heart Disease Down, Up for Blood Pressure, Irregular Heartbeat
HealthDay News
Number of pregnant women on narcotic painkillers, heroin doubles
Medical Xpress
Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells
The Street

Site Map | Privacy Policy | Contact Webmaster
Site Mission Statement, Intended Audience, Editorial Policy, Advertising Policy
This Page Last Updated 11/24/14
If you feel that your intellectual property being infringed upon by us,
e-mail the webmaster and we will remove the content.